BCL2 and lymphoma: Exposure of the lymphoma cells to nanomolar doses of KPT-9274 led to a significant reduction in the expression of Bcl-2 (pro-survival marker) and enhanced expression of pro-apoptotic markers, such as cleaved-Caspase-3 and cleaved-PARP (Figure 2C and Figure S4).